<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec id="j_raon-2017-0023_s_100">
<h3>Background</h3>
<p>There have been few reports about high total dose hypofractionated proton beam therapy for central lung cancer. The aim of this study was to examine retrospectively the safety and efficacy of high total dose hypofractionated proton beam therapy for central lung cancer.</p></sec>
<sec id="j_raon-2017-0023_s_101">
<h3>Patients and methods</h3>
<p>Patients treated by proton beam therapy for central lung cancer located less than 2 cm from the trachea, mainstem bronchus, or lobe bronchus were included in this study. All patients received 80 Gy of relative biological dose effectiveness (RBE) in 25 fractions with proton beam therapy over 5 weeks between January 2009 and February 2015. The toxicities were evaluated using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer criteria.</p></sec>
<sec id="j_raon-2017-0023_s_103">
<h3>Results</h3>
<p>Twenty patients, including 14 clinically inoperable patients (70%), received proton beam therapy for central lung cancer. The median patient age was 75 years (range: 63–90 years), the median follow up time was 27.5 months (range: 12–72 months), and the median tumor diameter was 39.5 mm (range: 24–81 mm). All patients were followed for at least 20 months or until death. The 2-year overall survival rate was 73.8% (100% in operable patients, and 62.5% in inoperable patients), and the 2-year local control rate was 78.5%. There was no Grade 3 or higher toxicities, including bronchial stricture, obstruction, and fistula.</p></sec>
<sec id="j_raon-2017-0023_s_104">
<h3>Conclusions</h3>
<p>The present study suggests that a high total dose hypofractionated proton beam therapy for central lung cancer was safe and feasible.</p></sec>
</abstract>

Background
There have been few reports about high total dose hypofractionated proton beam therapy for central lung cancer. The aim of this study was to examine retrospectively the safety and efficacy of high total dose hypofractionated proton beam therapy for central lung cancer.

Patients and methods
Patients treated by proton beam therapy for central lung cancer located less than 2 cm from the trachea, mainstem bronchus, or lobe bronchus were included in this study. All patients received 80 Gy of relative biological dose effectiveness (RBE) in 25 fractions with proton beam therapy over 5 weeks between January 2009 and February 2015. The toxicities were evaluated using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer criteria.

Results
Twenty patients, including 14 clinically inoperable patients (70%), received proton beam therapy for central lung cancer. The median patient age was 75 years (range: 63–90 years), the median follow up time was 27.5 months (range: 12–72 months), and the median tumor diameter was 39.5 mm (range: 24–81 mm). All patients were followed for at least 20 months or until death. The 2-year overall survival rate was 73.8% (100% in operable patients, and 62.5% in inoperable patients), and the 2-year local control rate was 78.5%. There was no Grade 3 or higher toxicities, including bronchial stricture, obstruction, and fistula.

Conclusions
The present study suggests that a high total dose hypofractionated proton beam therapy for central lung cancer was safe and feasible.

High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer

Radiology and Oncology

This work is licensed under the Creative Commons Attribution 4.0 International License.

Background
There have been few reports about high total dose hypofractionated proton beam therapy for central lung cancer. The aim of this study was to examine...

High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer

Article Category: Research Article

Data publikacji: 16 cze 2017

Zakres stron: 324 - 330

Otrzymano: 17 sty 2017

Przyjęty: 14 maj 2017

DOI: https://doi.org/10.1515/raon-2017-0023

© 2017 Takashi Ono, Tomonori Yabuuchi, Tatsuya Nakamura, Kanako Kimura, Yusuke Azami, Katsumi Hirose, Motohisa Suzuki, Hitoshi Wada, Yasuhiro Kikuchi, Kenji Nemoto

This work is licensed under the Creative Commons Attribution 4.0 International License.